The soluble adhesion molecules P-selectin (sP-selectin) and intercellular adhesion molecule-1 (sICAM-1) are derived from platelets and endothelial cells. Circulating concentrations of these soluble adhesion molecules are raised in patients with atherosclerosis and following percutaneous transluminal coronary angioplasty (PTCA). We have investigated the effects of vitamin E supplements (800 IU/day) on circulating plasma ICAM-1 and P-selectin levels pre-and post-PTCA. Patients, randomized to group, were pre-treated with vitamin E or placebo (soybean oil) for 1 month before routine PTCA. Plasma sICAM-1 and sP-selectin were measured by enzyme-linked immunosorbent assay on blood taken immediately pre-and post-PTCA. Total protein and a-tocopherol were measured on the same samples. Plasma a-tocopherol concentrations increased in patients receiving vitamin E: 19´1 (1´5) [mean (standard error of the mean, SEM)] mg/mL post-PTCA versus 13´9 (0´6) mg/ mL pre-PTCA (n=23; P50´01). Plasma sP-selectin and sICAM-1 levels were not signi®cantly increased following PTCA in the vitamin E group. Pre-angioplasty mean (SEM) plasma sP-selectin concentration in the vitamin E group was 8´83 (0´97) ng/mg protein; the corresponding mean post-angioplasty value was 9´34 (0´89) ng/mg protein (P=0´85). The mean (SEM) pre-angioplasty sICAM-1 concentration in this group was 2´18 (0´24) ng/mg protein, and was 2´20 (0´23) ng/ mg protein following angioplasty (P=0´84). In the placebo group (n=24) there was a signi®cant increase in mean (SEM) sP-selectin concentration following angioplasty, from 7´48 (0´73) to 9´70 (0´78) ng/mg protein (P50´05). The change (mean, SEM) in plasma sP-selectin concentration following angioplasty was signi®cantly greater for the placebo group [2´22 (0´50) ng/mg protein] than for the group receiving vitamin E [0´50 (0´50) ng/mg protein] (P50´02). This difference remained signi®cant (P50´05) even after adjustment for pre-angioplasty P-selectin concentrations. Mean (SEM) plasma sICAM-1 concentrations remained unchanged following angioplasty [preangioplasty: 2´16 (0´20) ng/mg protein; post-angioplasty: 1´97 (0´13) ng/mg protein]. Vitamin E may therefore limit platelet or endothelial activation during PTCA.
Vitamin E is a potent, lipid-soluble plasma antioxidant. Taking supplements of vitamin E has been shown to be associated with reduced risk of coronary heart disease in men and women. 1, 2 Vitamin E has also been shown to reduce morbidity, though not mortality, in patients with established coronary heart disease. 3 The mechanism by which vitamin E exerts these effects is unclear, but it has been shown to inhibit platelet aggregation 4±7 and adhesion. 4, 8 Vitamin E is lipophilic and has also been shown to inhibit the oxidative modi®cation of lowdensity lipoprotein, a process thought to be of crucial importance in atherogenesis. We have also previously shown that a-tocopherol (the most biologically potent isomer of vitamin E) has important direct effects on platelets, vascular endothelial cells and smooth muscle cells. 9±11 Adhesion molecules are membrane-associated molecules that mediate the interactions between cells, including platelets, endothelial cells and leucocytes. Some of these molecules are cleaved from the cell surface and enter the circulation. Elevated levels of these soluble adhesion molecules appear to be associated with cell activation, and have been reported following myocardial infarction,stroke and cardiovascularsurgery. 12±17 Elevated levels have also been reported in patients with angina 18 and dyslipidaemia 19 and following coronary angioplasty. 14 In the present study, we have measured the plasma concentrations of the soluble adhesion molecules P-selectin (sPselectin) and intercellular adhesion molecule-1 (sICAM-1) in patients undergoing angioplasty for established coronary artery disease.
MATERIALS AND METHODS

Materials
Vitamin E and placebo capsules were kindly donated by Dr Rupert Mason of Bioglan Ltd (Hitchin, UK). Vitamin E standard and quality control material were obtained from Bio-Rad Laboratories (Hemel Hempstead, UK). Enzymelinked immunosorbentassay (ELISA) kits for the measurement of plasma sP-selectin and sICAM-1 and Parameter 1 quality control serum were obtained from R&D Systems (Abingdon, UK). Folin±Ciocalteu phenol reagent was purchased from BDH Chemicals (Poole, UK). All other reagents were from Sigma Chemical Co (Poole, UK).
Subjects
Patients with angiographically de®ned coronary heart disease were recruited from the cardiology clinics at Glen®eld General Hospital, Leicester. Each patient had 470% stenosis of one or more epicardial coronary arteries, and subsequently underwent routine percutaneous transluminal coronary angioplasty (PTCA) as part of the Coronary Vitamin E Restenosis Trial (COV-ERT). With informed consent, and approval of the local ethical committee, patients were randomly and blindly allocated to receiving vitamin E (800 IU/day), or a placebo capsule of soybean oil. Patients took the placebo or vitamin E for 4 weeks before angioplasty.
Blood sampling
Whole blood samples for measurement of lipids (total cholesterol, triglycerides and high-density lipoprotein cholesterol) and vitamin E (atocopherol) were taken following a 12-h overnight fast. Blood for measurement of soluble adhesion molecules was taken immediately preand immediately post-angioplasty from the femoral artery via a catheter.
Lipid pro®les
Plasma was obtained from fasting blood samples collected into lithium heparin tubes (1´5 IU/mL heparin) and centrifuged at 1500 g for 10 min at 48C. Measurements of plasma total cholesterol and triglycerides were made using an Ektachem 700XR Analyser C series (Ortho Diagnostics, Rochester NY, USA).
Plasma vitamin E concentrations
Plasma samples were obtained from lithium heparin blood samples as described above, and stored at 7708C in the dark until analysis.Plasma vitamin E was determined by high-performance liquid chromatography using a modi®cation of the method of Bieri et al. 20 Brie¯y, 200 mL of internal standard (10 mg/mL d-tocopherol in isopropanol) was added to 200 mL of serum and vortex mixed. Aqueous ammonium sulphate (3´9 mol/L, 200 mL) was added and again vortex mixed. After centrifugation at 4000 rpm for 5 min, 50 mL of the supernatant was separated using a Prodigy 5-mm ODS2 column (1506 4´6 mm) (Phenomenex Ltd, Maccles®eld, UK), using methanol as the mobile phase at a¯ow rate of 2 mL/min. Peaks were detected at 290 nm. Retention times for dand a-tocopherol were 3´3 and 4´2 min, respectively. Inter-assay coef®cients of variation were 5´1% and 3´1% at vitamin E concentrationsof 3094 and 10 846 mg/L, respectively.
Plasma soluble adhesion molecule assay
sP-selectin and sICAM-1 concentrations were measured using commercially available ELISA kits according to the manufacturer's instructions. All samples and Parameter control serum were diluted 1:20 using the sample diluent provided with the kit. Diluted standard, sample or control serum (100 mL) was added in duplicate to wells of the microtitre plate provided, which had been previously coated with a murine monoclonal antibody to human sP-selectin or sICAM-1. A 100-mL aliquot of diluted horseradish peroxidase conjugated antisoluble adhesion molecule was added to each well. The microtitre plate was covered with a plastic plate sealer and incubated at room temperature for 1 h. The wells were then washed three times with the wash buffer provided using an automated Anthos plate washer (Labtec Instuments, Salburg, Austria). Excess wash liquid was removed by inverting the plate over a paper towel. Tetramethylbenzidine (TMB) solution (100 mL) was added to each well, and the plate was incubated for 15 min at room temperature. The reaction was stopped by adding 100 mL of sulphuric acid, and the optical density of each well at 450 nm was determined within 30 min using an automated Anthos HTIII plate reader (Labtec Instruments).
Protein assay (Lowry method)
In order to correct for any dilution effects following angioplasty, total plasma protein concentrations were determined for each sample; the soluble adhesion molecule concentrations were expressed as ng/mg protein. Brie¯y, plasma samples were diluted 5-fold in distilled water and 5, 10 and 20 mL of diluted sample were added to plastic tubes (Sarstedt, Leicester, UK) in duplicate. Bovine serum albumin was used to construct a standard curve. Solutions of sodium carbonate (20 g/L) in 4 g/L sodium hydroxide, 10 g/L copper sulphate and 20 g/L potassium sodium tartrate were mixed in a ratio of 100:1:1; 1 mL was added to each tube, vortex mixed and incubated at room temperature for 10 min. Then 100 mL of 50% Folin±Ciocalteu phenol reagent in distilled water was added to each tube. The tubes were vortex mixed and incubated at room temperature for 30 min; then the absorbance was read at 650 nm using a UV-160A UV±Visible spectrophotometer (Shimadzu Corporation, Kyoto, Japan). Protein concentrations were determined by reference to the standard curve.
Statistical analysis
Results are expressed as mean (SEM). Signi®cance was assessed by the Mann±Whitney U-test for non-normally distributed data, paired or unpaired t-tests for normally distributed data, and w 2 tests for categorical data using Minitab version 9.2 software (Minitab Inc, State College PA, USA). Analysis of covariance was performed to adjust the change between pre-and post-angioplasty P-selectin values for pre-angioplasty concentrations.
RESULTS
Basal patient characteristics
Forty-seven patients were randomly allocated to receive either placebo or vitamin E prior to the PTCA procedure: 23 received vitamin E (800 IU/day) and 24 received placebo. Selected demographic, clinical and biochemical characteristics of the placebo and vitamin E groups are shown in Tables 1 and 2. The group assigned to receive vitamin E consisted of 15 men and eight women with a mean (SEM) age of 62 (2) years (range 51±84 years). The placebo group comprised 19 men and ®ve women with a mean age of 61 (2) years (range 44±73 years). There were no signi®cant differences between the two groups at baseline. The drug treatment received by each individual was unaltered over the course of the study, and is summarized in Table 1 .
Effect of placebo and vitamin E supplementation on plasma lipid and vitamin E levels
There were no signi®cant changes observed in mean plasma total cholesterol or triglyceride concentrations following supplementation in either the vitamin E group or the placebo group (Table 2) . Vitamin E supplementation at 800 IU/day produced a signi®cant increase in mean (SEM) plasma vitamin E concentration at the time of PTCA [19´1 (1´5) mg/L versus 13´9 (0´60) mg/L; P50´01] ( Table 2) . Placebo supplementation was not associated with any signi®cant changes in mean plasma vitamin E concentration ( Table 2) .
Effect of placebo and vitamin E supplementation on soluble adhesion molecules
Soluble P-selectin and sICAM-1 concentrations were determined immediately before and immediately following the PTCA procedure in the vitamin E and placebo groups. There was no signi®cant difference in mean (SEM) pre-PTCA concentrations of sP-selectin [8´83 (0´97) ng/mg protein versus 7´48 (0´73) ng/mg protein; P=0´10] and sICAM-1 [2´18 (0´69) ng/mg protein versus 2´16 (0´77) ng/mg protein; P=0´95] between the vitamin E and placebo groups ( Table  2 ). Mean (SEM) plasma concentrations of sPselectin were signi®cantly increased post-PTCA [9´70 (0´78) ng/mg protein] compared with pre-PTCA concentrations [7´48 (0´73) ng/mg protein] in the placebo group (P=0´045). However, there was no signi®cant change observed in the group that received vitamin E, in whom mean (SEM) concentrations of plasma sP-selectin were 9´34 (0´89) ng/mg protein post-PTCA compared with 8´83 (0´97) ng/mg protein pre-PTCA (P=0´54) (Fig. 1) . The change in mean (SEM) plasma sPselectin concentrations following angioplasty was also signi®cantly greater in the placebo group [2´22 (0´50) ng/mg protein] than in the vitamin E group [0´50 (0´50) ng/mg protein; P50´02]. This remained signi®cant (P50´05) after adjustment for pre-angioplasty concentration using the method of Altman. 21 Mean (SEM) plasma concentrations of ICAM-1 pre-PTCA were 2´18 (0´77) ng/mg protein and 2´16 (0´62) ng/mg protein for the vitamin E and placebo groups, respectively (P=0´95), and were 2´20 (0´69) ng/ mg protein and 1´97 (0´38) ng/mg protein post-PTCA for these groups, respectively (P=0´39).
Hence these values were not signi®cantly altered for either group following PTCA (P40´05).
DISCUSSION
Effects of vitamin E supplementation on plasma lipid and vitamin E levels
The basal characteristics of both study groups were matched in terms of age, gender distribution and other coronary risk factors, including lipoprotein pro®le, smoking habit, diabetes and hypertension. Dietary supplementation with vitamin E for 4 weeks prior to PTCA led to a signi®cant increase in plasma a-tocopherol, whereas placebo treatment had no signi®cant effect. Despite the previously reported cholesterol-lowering properties of a-tocopherol, 22 supplementation with placebo or vitamin E at a dose of 800 IU/day was not associated with any sig-ni®cant effects on plasma total cholesterol or triglycerides. These ®ndings agree with other reports. 7, 23 
Effects of vitamin E on plasma soluble adhesion molecules after PTCA
The adhesion molecule P-selectin is located in both endothelial cells and platelets, where, upon activation, it may be expressed on the cell surface and secreted into the plasma. The origin of sP-selectin may be from one or both of these cell types; however, it has been suggested that platelets are the major source of circulating sPselectin. 24, 25 Platelet activation has been demonstrated to occur following PTCA. 26±29 The observed increase in sP-selectin levels post-PTCA in the placebo group may support the notion that PTCA produces activation of platelets. Vitamin E supplementation prevented this increase in sP-selectin levels post-PTCA, which may indicate that vitamin E has the ability to limit the activation of platelets during PTCA. The failure to observe any alteration in soluble ICAM-1 levels post-PTCA in either the placebo or vitamin E supplemented group may suggest that any endothelial activation produced is not immediate enough to result in alterations in the levels of these two glycoproteins, or that the mechanism by which activation or damage occurs does not result in increased levels of either of these two molecules. Vitamin E supplementation at 600 IU/day has been demonstrated to reduce sP-selectin in hypercholesterolaemic patients. 30 This may represent an inhibition of the enhanced activation that occurs in hypercholesterolaemic subjects. 31, 32 In support of this hypothesis is the lower excretion of urinary 11-dehydrothromboxane B 2 (an established marker of platelet activation), which also occurs following vitamin E supplementation. 30 A possible mechanism by which vitamin E prevents the elevation of soluble P-selectin post-PTCA is through its inhibitory action on protein kinase C (PKC). 33, 34 PKC activation may induce P-selectin expression; 35 furthermore, lysophosphatidylcholine-induced P-selectin expression can be signi®cantly reduced by PKC inhibitors, such as 7-hydroxystaurosporine and N,N,Ntrimethylsphingosine. 36 Therefore, the previously reported ability of vitamin E to inhibit PKC 34, 37 may in part explain the unaltered sP-selectin levels post-PTCA in the group supplemented with vitamin E.
CONCLUSIONS
The observed increase in soluble P-selectin levels post-PTCA in the placebo group may support the notion that PTCA results in activation of platelets and/or endothelial cells. The fact that this increase was abolished by treatment with vitamin E suggests that vitamin E has the ability to limit activation of these cells during PTCA, and supports our previous in vitro data, which showed that a-tocopherol inhibits thrombininduced platelet aggregation. 9 By contrast, the observation that levels of soluble ICAM-1 were unchanged following PTCA in either group of subjects suggests that vitamin E supplementation primarily acts to reduce the activation of platelets, rather than endothelial cells, following angioplasty.
